Abstracts tagged "modifiable risk and rheumatoid arthritis (RA)"

Abstract Number: 1539 • 2015 ACR/ARHP Annual Meeting
Control of Modifiable Cardiovascular Risk Factors in Rheumatoid Arthritis Patients Compared to Traditional High-Risk Cardiovascular Disease Patients
Brian LaMoreaux¹, Alexa Meara² and Wael N. Jarjour³, ¹Rheumatology, The Ohio State University, Columbus, OH, ²Internal Medicine/Rheumatology, The Ohio State University, Columbus, OH, ³Department of Internal Medicine, Division of Immunology and Rheumatology, The Ohio State University Medical Center, Columbus, OH
Background/Purpose: Rheumatoid arthritis (RA) is a chronic systemic inflammatory autoimmune disease affecting one percent of the population. The main cause of mortality among RA patients…
Abstract Number: 421 • 2013 ACR/ARHP Annual Meeting
Enhanced Cardiovascular Risk Factor Screening In Rheumatoid Arthritis: Does This Have a Sustained Impact?
Mark J Ponsford¹, Jennifer K. Cooney², Bethany Anthony³, Fflur A. Huws⁴, Lauren Evans¹, Jeanette Thom⁵ and Yasmeen Ahmad¹, ¹Betsi Cadwaladr University Health Board, Peter Maddison Research Centre, Llandudno, United Kingdom, ²School of Sport, Health and Exercise Sciences, School of Sport, Health and Exercise Sciences, Bangor University, George Building, Bangor, Gwynedd, LL57 2PZ, UK., Bangor, United Kingdom, ³Health and Exercise Sciences, School of Sport, Health and Exercise Sciences, Bangor University, George Building, Bangor, Gwynedd, LL57 2PZ, UK., Bangor, United Kingdom, ⁴Health and Exercise Sciences, Bangor University, School of Sport, Health and Exercise Sciences, Bangor University, George Building, Bangor, Gwynedd, LL57 2PZ, UK., Bangor, United Kingdom, ⁵School of Sport, Health and Exercise Sciences, Bangor University, George Building, Bangor, Gwynedd, LL57 2PZ, UK., Bangor, United Kingdom
Background/Purpose: Rheumatoid Arthritis (RA) patients face a burden of cardiovascular disease (CVD) twice that of the general population. RA patients have reduced physical fitness, a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].